Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Thursday, 10 September 2020

SCENESSE® in DNA Repair

CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP) A separate media release – in simple non-technical terms – has been lodged outlining the aims and objectivesof the DNA Repair Program. CLINUVEL will post background information on XP to its social media channels:Twitter | Facebook | Instagram | LinkedIn EXECUTIVE SUMMARY CLINUVEL […]

Download PDF
 
 

On 27 August 2020 CLINUVEL released its Preliminary Financial Report for FY2020. CFO Darren Keamy and CEO and Managing Director Dr Philippe Wolgen speak with Head of Investor Relations, Malcolm Bull, following the results release. A corporate presentation was also released on 27 August and can be accessed here.

Download PDF
 
 
Tuesday, 01 September 2020

Proposed issue of Securities

Download PDF

Download PDF
 
 

CLINUVEL OPENS VALLAURIX R&D CENTRE IN SINGAPORE Bespoke Research & Development Centre to advance innovative pharmaceutical and OTC products The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd. The extensive bespoke analytical and biological laboratories and offices will house and […]

Download PDF
 
 

Opening of VALLAURIX R&D facilities in Singapore

Download PDF
 
 

Download PDF Previous Next

Download PDF
 
 
Thursday, 27 August 2020

CLINUVEL Declares Full Year Dividend

CLINUVEL Declares Full Year Dividend Dividend/Distribution – CUV

Download PDF
 
 
Thursday, 27 August 2020

CLINUVEL Full Year Results

CLINUVEL Full Year Results 2020

Download PDF
 
 

Appendix 4E and Preliminary Financial Report 2020

Download PDF
 
 
Friday, 31 July 2020

Appendix 4C – quarterly

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 April to 30 June 2020. All figures are rounded and reported in Australian dollars. Key Highlights: •  Cash receipts $10,403,000 over the quarter •  Net cash flow of $7,175,000 •  Cash and equivalents on hand increased […]

Download PDF
 
 
Thursday, 23 July 2020

Kommuniqué IV

Liebe Aktionäre, Freunde, Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für die mehr als 600.000 Menschen, die ihr Leben verloren haben und unzählige weitere, die von dieser Pandemie betroffen sind, […]

Download PDF
 
 
Wednesday, 22 July 2020

CLINUVEL Newsletter

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends, As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we need to pause for the more than 600,000 people who have lost their lives and countless more impacted by […]

Download PDF
 
Friday, 08 May 2020

Chair Letter to Shareholders

Fellow shareholders,In my March letter I wished all good health during uncertain times. It is now clear the extent of damage COVID-19 has caused and will cause for many years in the future. I want …

Download PDF
 

Innovative drug launched for rare, isolating, “light intolerance” disorder Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or burning reactions from exposure to light, are welcoming an …

www.clinuvel.com

 

1 SCENESSE® (afamelanotide 16mg) is approved in the European Union as an orphan medicinal product for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is approved in the USA to increase pain free light exposure in adult EPP patients with a history of phototoxicity. Information on the product, including the approved prescribing information, can be found on CLINUVEL’s website at www.clinuvel.com.

2 Biolcati et al. (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. The British Journal of Dermatology. 172(6), 1601–1612. Langendonk et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. The New England Journal of Medicine. 373(1), 48–59. Wensink et al. (2020). Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatology. EPub 18 March 2020.

Download PDF

 

CLINUVEL PHARMACEUTICALS LTD today announced that US insurance companies have agreed to reimburse SCENESSE® (afamelanotide) for patients diagnosed with erythropoietic protoporphyria (EPP).1SCENESSE® was approved by the US Food and Drug Administration (FDA) in October 2019 …

www.clinuvel.com.

2 Further details and terms and conditions are available from www.scenesse.com. This site is intended for US residents only.

Download PDF

 
Monday, 23 March 2020

CLINUVEL Kommuniqué II

Sehr geehrte Aktionäre, liebe Freunde,im Laufe des Jahres haben wir einen deutlichen Rückgang der globalen Aktienmärkte erlebt, der den Wertverlust von CLINUVEL noch verstärkt hat. Obwohl dies für viele unserer Aktionäre, einschließlich der Mitarbeiter, die …

Download PDF
 
Thursday, 19 March 2020

CLINUVEL Newsletter

Dear shareholders, friends,As the year unfolds, we have witnessed the significant downturn of global stock markets which has compounded the decline of CLINUVEL’s value. While regretful and painful for many of our shareholders, including staff …

Download PDF
 
Thursday, 12 March 2020

Chair Letter to Shareholders

Fellow shareholders,Let me start a first welcome letter by wishing you a successful and great year ahead without health issues, pertinent at the time that Corona virus is taking over the world news.Since appointed in …

Download PDF
 
Wednesday, 29 January 2020

CLINUVEL Kommuniqué I

Sehr geehrte Aktionärinnen und Aktionäre, liebe FreundeIm Namen des CLINUVEL-Ausschusses wünsche ich Ihnen allen ein gutes neues Jahr in der Hoffnung, dass es Ihnen Gesundheit und Wohlstand verleiht. Wir bedanken uns vielmals bei Stan McLiesh, …

Download PDF
 
Thursday, 16 January 2020

CLINUVEL Newsletter

Dear shareholders, friendsOn behalf of the CLINUVEL Board, I wish you all a good new year in the hope that it confers you with good health and prosperity, in that particular sequence. We thank and …

Download PDF
 
Thursday, 05 December 2019

Appendix 3B

 New issue announcement, application for quotation of additional securities and agreement. 

Download PDF
 
Monday, 02 December 2019

CEO Letter

Dear shareholders, On 8 October 2019, CLINUVEL obtained its first and historic US Food and Drug Administration (FDA) approval, some 39 years since the afamelanotide technology was first discovered in a university laboratory. On this day …

Download PDF